Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

NEWS

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024


MiNK Therapeutics (NASDAQ: INKT) announced two poster presentations at the Society for Immunotherapy of Cancer's 29th Annual Meeting in Houston, Texas, from November 6-10, 2024. The presentations will showcase new preclinical data from MiNK's iNKT cell programs, agenT-797 and PRAME-TCR.

The first presentation, titled 'AgenT-797 cell therapy can be combined with next-generation immune checkpoint inhibitors (ICI) and / or bi-specific engagers to improve anticancer response,' is scheduled for Friday, November 8th (Abstract Number: 753).
The second presentation, 'PRAME-TCR iNKT cell therapy: Opportunity for best-in-class off-the-shelf solid tumor therapy targeting PRAME,' will take place on Saturday, November 9th (Abstract Number: 374).
MiNK Therapeutics is a clinical-stage biopharmaceutical company focusing on the development of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
1760 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    2962Followers
    109Following
    31KVisitors
    Follow